PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
43.23
+0.34 (0.79%)
Nov 22, 2024, 4:00 PM EST - Market closed
PTC Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 900.66 | 937.82 | 698.8 | 538.59 | 380.77 | 306.98 | Upgrade
|
| Revenue Growth (YoY) | 12.84% | 34.20% | 29.75% | 41.45% | 24.04% | 15.96% | Upgrade
|
| Cost of Revenue | 601.3 | 732.05 | 696.17 | 573.01 | 442.99 | 269.59 | Upgrade
|
| Gross Profit | 299.37 | 205.77 | 2.63 | -34.42 | -62.22 | 37.39 | Upgrade
|
| Selling, General & Admin | 292.52 | 332.54 | 326 | 285.77 | 244.46 | 202.54 | Upgrade
|
| Operating Expenses | 427.12 | 555.18 | 442.55 | 340.52 | 281.36 | 230.19 | Upgrade
|
| Operating Income | -127.76 | -349.4 | -439.93 | -374.94 | -343.58 | -192.8 | Upgrade
|
| Interest Expense | -171.01 | -128.88 | -94.87 | -86.02 | -56.35 | -12.49 | Upgrade
|
| Other Non Operating Income (Expenses) | 10.61 | 11.81 | -31.92 | -45.19 | 51.63 | 11.53 | Upgrade
|
| EBT Excluding Unusual Items | -286.76 | -466.48 | -566.71 | -506.15 | -348.3 | -193.76 | Upgrade
|
| Merger & Restructuring Charges | -1.49 | - | - | - | -0.3 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 5.45 | -1.98 | -13.29 | -12.69 | 33.56 | 2.19 | Upgrade
|
| Asset Writedown | - | -217.8 | -33.38 | - | -54 | - | Upgrade
|
| Other Unusual Items | -138.38 | -9.86 | 25.9 | 0.5 | -33.89 | -48.36 | Upgrade
|
| Pretax Income | -425.47 | -696.11 | -587.49 | -518.34 | -402.93 | -239.93 | Upgrade
|
| Income Tax Expense | 27.73 | -69.51 | -28.47 | 5.56 | 35.23 | 11.65 | Upgrade
|
| Net Income | -453.2 | -626.6 | -559.02 | -523.9 | -438.16 | -251.58 | Upgrade
|
| Net Income to Common | -453.2 | -626.6 | -559.02 | -523.9 | -438.16 | -251.58 | Upgrade
|
| Shares Outstanding (Basic) | 76 | 75 | 72 | 70 | 66 | 59 | Upgrade
|
| Shares Outstanding (Diluted) | 76 | 75 | 72 | 70 | 66 | 59 | Upgrade
|
| Shares Change (YoY) | 3.08% | 4.34% | 1.79% | 6.72% | 12.17% | 26.38% | Upgrade
|
| EPS (Basic) | -5.93 | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | Upgrade
|
| EPS (Diluted) | -5.93 | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | Upgrade
|
| Free Cash Flow | -186.27 | -186.86 | -388.67 | -279.55 | -211.91 | -112.4 | Upgrade
|
| Free Cash Flow Per Share | -2.44 | -2.50 | -5.42 | -3.97 | -3.21 | -1.91 | Upgrade
|
| Gross Margin | 33.24% | 21.94% | 0.38% | -6.39% | -16.34% | 12.18% | Upgrade
|
| Operating Margin | -14.18% | -37.26% | -62.95% | -69.62% | -90.23% | -62.80% | Upgrade
|
| Profit Margin | -50.32% | -66.81% | -80.00% | -97.27% | -115.07% | -81.95% | Upgrade
|
| Free Cash Flow Margin | -20.68% | -19.92% | -55.62% | -51.90% | -55.65% | -36.61% | Upgrade
|
| EBITDA | 21.85 | -112.81 | -311.09 | -310.81 | -300.09 | -160.62 | Upgrade
|
| EBITDA Margin | 2.43% | -12.03% | -44.52% | -57.71% | -78.81% | -52.32% | Upgrade
|
| D&A For EBITDA | 149.6 | 236.59 | 128.84 | 64.13 | 43.49 | 32.18 | Upgrade
|
| EBIT | -127.76 | -349.4 | -439.93 | -374.94 | -343.58 | -192.8 | Upgrade
|
| EBIT Margin | -14.18% | -37.26% | -62.95% | -69.62% | -90.23% | -62.80% | Upgrade
|
| Revenue as Reported | 900.66 | 937.82 | 698.8 | 538.59 | 380.77 | 306.98 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.